The efficacy of pembrolizumab was confirmed by the results of the phase II/III trial KEYNOTE-010, which enrolled patients with previously treated advanced NSCLC and PD-L1 expression on at least 1% of tumor cells and compared OS and PFS for three treatment arms: pembrolizumab (two arms, 2 or 10 mg/kg) or docetaxel (one arm, 75 mg/m2). The gene discussed is CD274; the disease is non-small cell lung carcinoma.